Clinical Trials in New York

Showing 901-920 of 19,464 trials

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

NCT06362265

The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.

Type 2 Diabetes Mellitus

Eli Lilly and Company15 participantsStarted Oct 2024

Los Angeles, California, United States • Atlanta, Georgia, United States • Columbus, Georgia, United States +7 more locations

COMPLETEDPhase 1/2< 1 mile

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus

BacteremiaStaphylococcus AureusStaphylococcus Aureus Bacteremia+2 more

Armata Pharmaceuticals, Inc.56 participantsStarted Apr 2022

Tucson, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +25 more locations

A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

Find Trials by Condition in New York

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer

Innovative Web-based Service Platform Called Adult Wellbeing CheckUp (AWC) to Assess Older Adults Wellbeing, Obtain Evidence-based Recommendations, and Receive Support to Take Action.

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Prospective Multisite Study of Quality of Life in Pediatric Intestinal Failure

Patient Reported Outcomes With WaveLight LASIK

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms